|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
60 Paya Lebar Road,Singapore,Singapore,SG
|
|
Sengenics is a functional proteomics company that leverages its patented KREXTM technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics.The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.The company has 19 granted patents in the USA, UK, EU, Japan, Canada and Australia.
|
Sengenics Email Formats | Example Email Formats | Percentage |
---|---|---|
{first} | [email protected] |
50%
|
The widely used Sengenics email format is {first} (e.g. [email protected]) with 50% adoption across the company.
To contact Sengenics customer service number in your country click here to find.
Jerry Williamson is the CEO of Sengenics. To contact Jerry Williamson email at [email protected] or [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.